Methods of treating C5 mediated complement-associated conditions with anti-C5 antibodies having improved pharmacokinetics
US-9107861-B1 · Aug 18, 2015 · US
Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
US12169205B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12169205-B2 |
| Application number | US-201815963455-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 26, 2018 |
| Priority date | Dec 19, 2014 |
| Publication date | Dec 17, 2024 |
| Grant date | Dec 17, 2024 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The disclosure provides anti-myostatin antibodies and methods of making and using the same. Nucleic acids encoding the anti-myostatin antibodies and host cells comprising the nucleic acids are also provided. The anti-myostatin antibodies have uses that include treating a muscle wasting disease, reducing body fat accumulation, and increasing mass and strength of muscle tissue. The disclosure also provides polypeptides containing a variant Fc region and methods of making and using the same. Nucleic acids encoding the polypeptides and host cells comprising the nucleic acids are also provided. The polypeptides have uses that include suppressing the activation of immune cells; treating an immunological inflammatory disease, autoimmune disease, or viral infection; and increasing muscle mass and strength or reducing body fat accumulation.
First claim
Opening claim text (preview).
What is claimed is: 1. A polypeptide comprising a variant Fc region, wherein the variant Fc region comprises amino acid alterations in a parent Fc region at positions 234, 238, 264, 311, 330, and 343 according to EU numbering, wherein the parent Fc region comprises the amino acid sequence of any one of SEQ ID NO: 195-197, or 198, and wherein the variant Fc region comprises an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 195-197, or 198, respectively. 2. The polypeptide of claim 1 , wherein the parent Fc region comprises the amino acid sequence of SEQ ID NO: 195. 3. The polypeptide of claim 1 , wherein the polypeptide is an antibody or an Fc fusion protein. 4. The polypeptide of claim 1 , wherein the variant Fc region comprises the amino acid sequence of SEQ ID NO:352. 5. The polypeptide of claim 1 , wherein the variant Fc region comprises an amino acid sequence having at least 95% sequence identity to SEQ ID NO: 195-197, or 198.
Assignees
Inventors
Classifications
Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title
Complementarity determining region [CDR] · CPC title
Constant or Fc region; Isotype · CPC title
Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues · CPC title
Cells for production · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12169205B2 cover?
- The disclosure provides anti-myostatin antibodies and methods of making and using the same. Nucleic acids encoding the anti-myostatin antibodies and host cells comprising the nucleic acids are also provided. The anti-myostatin antibodies have uses that include treating a muscle wasting disease, reducing body fat accumulation, and increasing mass and strength of muscle tissue. The disclosure als…
- Who is the assignee on this patent?
- Chugai Pharmaceutical Co Ltd
- What technology area does this patent fall under?
- Primary CPC classification C07K16/22. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Dec 17 2024 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).